Icon

ACTOS (nda021073)- (EQ 15MG BASE,EQ 30MG BASE,EQ 45MG BASE)

PIOGLITAZONE HYDROCHLORIDE TAKEDA PHARMS USA
EQ 15MG BASE,EQ 30MG BASE,EQ 45MG BASE
Yes No
2016-Aug-09 Expired
None None
None No
ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes (non-insulin dependent diabetes mellitus, NIDDM). ACTOS is indicated for monotherapy. ACTOS is also indicated for use in combination with a sulfonylurea, metformin, or insulin when diet and exercise plus the single agent does not result in adequate glycemic control.
11 1 8
Total Other Developers 12
Drugs with Suitability No
EQ 15MG BASE ** ** - 5 -
EQ 30MG BASE ** ** - 5 -
EQ 45MG BASE ** ** - - 5
NDA Sales Available Total Generic Sales Available
Yes 7
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ********* ** ********* *****, *** *********** ** *******-**, ******-***, *********-**, ********, **************-** *****, *****, ***** (***) ***
****** ********* ** ***** ******* *********** **** ** ****, *-*** ** *-***, *-*** ** *-***, **** ** *-***/*/*/*, *-****, *-***, *-***, *-***, ***** ********** ****, ********, *** ******, ***** (***) ***
****** ********* ** ********* *************** *******, ***. *********** ** ******* *****, *** ***** ******, *******, *** **** (**) *****, ****** ****** (***) ***
****** **** ****** *** ****** ****** ******* ******* *********** **** **. **-*-*, ***** ** ***** ********** ******, *****, ********, *** ******, ***** (***) ***
****** **** ****** *** **** ***** ********** *.*.* *********** ********* ***/**, *******, *****, *** **, ***** ******** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** ********* ****** *** ******** ****** *** *********** **** ***** *** *****, ******, *** ****** (**) *****, ****** ****** (***) ***
****** ********* ****** *** ******** ****** ******* ******* *** *********** ****-**, ****** **. ** & **, ************* ******* ***- *********, ******** ******, **********, ********* ******, ***** (***) ***
****** ********* ****** *** ********* ****** ******* *********** ****-***, **. **.*** & ***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ***** ****** *** *** ***** ************ ******* *********** ****** **. ***, *** & ***, ******* ***** ******** ******* ** * *, *******-*******, ***-******, ****. - *********, *********, ******* ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** ******* *****, **** ****** **********,****** *****, ******** *****, ******** ******* ******, ***** (***) ***
****** ******** *** ******** ****** ************** **., ***. *********** ******* ****, ******, ******** ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.